Company development
August 2010
- Oxford BioDynamics granted UK Human Tissue Authority licence.
July 2010
- Oxford BioDynamics completes pilot study on Melanoma and Hepatocellular carcinoma.
June 2010
- Oxford BioDynamics signs development agreement with major pharmaceutical company based in Asia.
May 2010
- EpiSwtichTM robotic platorm installed.
April 2010
- Oxford BioDynamics certified as ISO 9001:2008 and 13485:2003 compliant.
March 2010
- First grant of the Oxford BioDyanamics core patent in South Africa.
February 2010
- New Oxford BioDynamics reference laboratory opens at 26, Beaumont Street, Oxford, OX1 2NP, UK.
January 2010
- Mrs Karen Koh becomes Director of Asia.
- Professor Lucien Peng-Jin Ooi joins the Scientific Advisory Board.
December 2009
- Oxford BioDynamics executes its first Development and End-user licence in Australia for skin cancer with Clinical Laboratories Pty Limited, a subsidiary of Healthscope Pty Limited.
September 2009
- Extension of the feasibility study between Oxford University and Oxford BioDynamics.
August 2009
- Oxford BioDynamics announces the results of its validation trial for a non-invasive breast cancer screening test. Based on blood sample analysis, the test identifies patients with all five sub-types of breast cancer - Luminal A, Luminal B, Her2+, Basal and Unclassified. With a 95% CI (Confidence Interval) the upper range of test senstivity is 97.8%, specificity 97% and positive predictive value 99.6%.
June 2009
- Collaboration agreement signed with the Queen Mary and Westfield College, Centre for Medical Oncology, Institute of Cancer, Barts and the London School of Medicine.
May 2009
- License agreement signed with Chronos Therapeutics Limited.
April 2009
- Oxford BioDynamics raises circa $4 million.
March 2009
- Formation of Oxford BioDynamics Hepa Pte Limited.
- Extension of the feasbility study between Oxford University and Oxford BioDynamics.
February 2009
- EpiSwtichTM assay gets approval for CE certification.
- Formation of Oxford BioDynamics Australia Pty Limited.
- Oxford BioDynamics invited to present at the XXII International Congress organised by The Arizona Heart Institute and International Congress Foundation, Phoenix, Arizona, USA.
January 2009
- Oxford BioDynamics assay - EpiSwitchTM - registered as its trademark.
December 2008
- Collaboration agreement signed with The Ludwig Institute For Cancer Research.
November 2008
- Dr Heiner Dreismann, former President and CEO of Roche Molecular Systems Inc., joined the board.
October 2008
- Oxford BioDynamics forms Oxford BioDynamics Cardiovascular Pte Limited in association with The Arizona Heart Institute (USA).
- Oxford BioDynamics signs a Collaboration Agreement with Centre Européen de Recherche en Biologie et en Médecine (CERBM) and the Institute de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France.
September 2008
- Oxford BioDynamics Limited sponsors the Summer School on Chromatin and Transcription, Spetses Island, Greece, and its key-note speaker Dr Ramin Shiekhattar (Center for Genomic Regulation, Barcelona).
- Extension of the feasbility study between Oxford University and Oxford BioDynamics.
June 2008
- Professor Karol Sikora appointed chairman of the Oxford BioDynamics advisory board.
May 2008
- Oxford BioDynamics Limited files UK patent application No: 0810051.3 on novel methods of diagnostics and gene-specific therapy.
- Oxford BioDynamics raises circa $6 million.
- Extension of the feasibility study between Oxford University and Oxford BioDynamics Limited.
January 2008
- Dr Alexandre Akoulitchev becomes Chief Scientific Officer.
- Oxford BioDynamics Reference Laboratory opens at Oxford University Begbroke Science Park, Yarnton OX5 1PF.
December 2007
- Alison Kibble appointed as a non-Executive Director on behalf of Oxford University.
October 2007
- Dr Aroul Ramadass becomes Director of Science and Innovation.
September 2007
- Initial agreement on a feasibility study conducted by Oxford University and Oxford BioDynamics.
June, 2007
- Exclusive Licence granted to Oxford BioDynamics Limited by The Chancellor, Masters, Scholars of the University of Oxford and Isis Innovation Limited.
- Software Assignment from Dr Aroul Ramadass to Oxford BioDynamics Limited.
- Christian Hoyer Millar becomes Managing Director.
April 2007
- Formation of Oxford BioDynamics Limited. Company Number: 6227084.
February 2007
- Formation of Oxford BioDynamics PTE Limited in Singapore. Company Number: 2007071129.
- Publication of an epigenetic study from the Akoulitchev laboratory in Nature (2007), Vol.445, 7128, pp.666-670.
February 2006
- Patent application (PCT/GB2207/000564) on novel diagnostics technology developed in the laboratory of Dr Alexandre Akoulitchev, Exeter College, University of Oxford.